Form 4: Alkermes VP Finance Exercises RSUs, Sells Shares

Alkermes' VP of Finance, Samuel Joseph Parisi, reported the exercise of restricted stock units and a subsequent sale of shares for tax purposes.

Summary

• Samuel Joseph Parisi, VP, Finance (Interim PAO) of Alkermes plc, reported changes in his beneficial ownership.
• On February 26, 2026, Parisi acquired 2,747 ordinary shares through the exercise of a restricted stock unit (RSU) award.
• Each restricted stock unit represents a contingent right to receive one ordinary share.
• Concurrently, Parisi disposed of 808 ordinary shares at a price of $30.73 per share, typically for tax withholding related to the RSU vesting.
• Following these transactions, Parisi's direct beneficial ownership of ordinary shares stands at 14,607.
• Parisi also holds 5,493 derivative securities in the form of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for executive compensation and do not indicate any new positive or negative developments for Alkermes plc.

Positives

• The vesting and exercise of restricted stock units represent a planned compensation event for the executive, indicating continued alignment with shareholder interests through equity ownership.

Negatives

• The sale of 808 ordinary shares, while common for tax withholding, reduces the executive's direct equity stake in the company.

Future Outlook

The remaining 5,493 restricted stock units held by Samuel Joseph Parisi are subject to a vesting schedule that commenced on February 26, 2025, with shares vesting in four equal annual installments.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of restricted stock units and subsequent tax-related sales, are common across all industries, particularly in publicly traded companies that use equity compensation to align executive incentives with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice in the biotechnology and pharmaceutical industries, similar to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which also utilize equity awards to attract and retain talent.
• The disposition of shares to cover tax obligations upon RSU vesting is a typical and expected event, aligning with common practices observed in executive compensation plans across the S&P 500.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned executive compensation event and not a discretionary sale based on new company performance.
• Employees: No direct impact mentioned.

Next Steps

• Future installments of the restricted stock unit award will continue to vest annually, commencing from February 26, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to executive compensation (RSU vesting and tax-related sale). It does not provide new material information regarding the company's operational performance, financial health, or strategic direction. Therefore, a seasoned investor or institution would likely maintain their current position, as this filing does not warrant a change in investment thesis.

Keywords

Alkermes, ALKS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Beneficial Ownership, Executive Compensation, Share Sale